Bharat Immunologicals (India) Buy Hold or Sell Recommendation

    BIBCL -- India Stock  

    INR 13.18  0.24  1.79%

    Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Bharat Immunologicals Biologicals Corp Ltd is 'Not Rated'. Macroaxis provides Bharat Immunologicals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIBCL positions. The advice algorithm takes into account all of Bharat Immunologicals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BIBCL buy-and-hold prospective. Check also Trending Equities.

    Time Horizon

    Risk Tolerance

    Symbol
    Execute Advice
    Sell Bharat ImmunologicalsBuy Bharat Immunologicals
    Not Rated
    For the selected time horizon Bharat Immunologicals Biologicals Corp Ltd has a risk adjusted performance of 0.43, jensen alpha of 1.26, total risk alpha of 0.81, sortino ratio of 0.0 and treynor ratio of 3.55
    This buy or sell advice tool can be used to cross verify current analyst consensus on Bharat Immunologicals and to analyze the company potential to grow in the current economic cycle. To make sure Bharat Immunologicals is not overpriced, please confirm all Bharat Immunologicals fundamentals including its Current Valuation, Gross Profit, Debt to Equity, as well as the relationship between Price to Book and Cash and Equivalents .

    Bharat Immunologicals Returns Distribution Density

    Mean Return1.32Value At Risk7.12
    Potential Upside0.99Standard Deviation3.28
     Return Density 
          Distribution 

    Bharat Immunologicals Alerts

    Trading Alerts and Improvement Suggestions

    Bharat Immunologicals is not yet fully synchronised with the market data
    Bharat Immunologicals generates negative expected return over the last 30 days
    Bharat Immunologicals has high historical volatility and very poor performance
    The company reported revenue of 347.99 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 48.93 M.
    Check also Trending Equities. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
    Search macroaxis.com